title: Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion.
abstract: A clinically refractory case of cutaneous sarcoidosis was successfully treated with infliximab infusion therapy at a dose of 5mg/kg. Skin lesions cleared dramatically and remain resolved during a 3(1/2) year follow-up, the longest follow-up reported to date. Ongoing biological drug therapy has been administered at a frequency of every 8-10 weeks. Despite cost and safety concerns, infliximab should be considered in cases of cutaneous sarcoidosis refractory to standard treatment protocols.
authors.affiliation: Departments of Dermatology, Baylor College of Medicine and Veterans Affairs Medical Center Houston, Texas, USA.
authors.forename: Ted
authors.initials: T
authors.lastname: Rosen
authors.forename: Christy
authors.initials: C
authors.lastname: Doherty
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001706:Biopsy; D003879:Dermatologic Agents / Q000008:administration & dosage*; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008875:Middle Aged; D009668:Nose Diseases / Q000188:drug therapy* / Q000473:pathology; D012507:Sarcoidosis / Q000188:drug therapy* / Q000473:pathology; D012871:Skin Diseases / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab